ipamorelin safety adverse effects clinical trial Side In Women ipamorelin clinical trials safety adverse
Description
Mielle J, Morel J, Elhmioui J, Combe B, Macia L, Dardalhon V, et al
PI3K/mTOR dual inhibitor NVP-BEZ235 decreases Mcl-1 expression and sensitizes ovarian carcinoma cells to Bcl-xL-targeting strategies, provided that Bim expression is induced
doi: 10.1007/s12035-023-03706-z 49 WeberJT
& Vinh, L
